Dried Blood Spots Part 2

Future Science Ltd, November 2010, Pages: 179

Dried blood spot (DBS) sampling involves spotting blood from a heel- or finger-prick onto a card which is then air dried and sealed in bags with desiccant for storage and shipping. The technique offers many advantages compared to traditional liquid blood or plasma samples including:

- Low blood volume requirements are beneficial in pediatric studies and enable serial bleeding from one animal, so reducing the number of animals used in studies
- Improved data quality in preclinical toxicokinetic and pharmacokinetic studies
- Less invasive and more patient-friendly than venous cannulation
- Cards can be stored at ambient conditions, reducing sample storage and transport costs

Although DBS has a long history of use in pediatric studies and in resource-limited settings, these advantages have generated significant current interest in DBS amongst bioanalysts, toxicologists, and pharmacokineticists who see the benefits of implementing DBS sampling in their drug development programs. Consequently, a large amount of research into the use of DBS is currently underway in pharmaceutical development laboratories worldwide.

The use of these samples can make life more difficult for the bioanalyst: smaller sample volumes have the potential to limit assay sensitivity and multiple card types and extraction solvents need to be investigated as part of method development; furthermore, the full implementation of DBS in pharmaceutical laboratories necessitates a switch from plasma to blood pharmacokinetic and toxicokinetic data; this means that both scientific and regulatory aspects will need to be considered to ensure that the use of DBS as replacement matrix for plasma in supporting drug development will meet everybody’s needs and requirements.

This is Part 2 of two Special Focus Issues of the peer-reviewed journal Bioanalysis and includes a mixture of review and research articles demonstrating the pharmaceutical, clinical and bioanalytical applications of DBS alongside papers illustrating advances in the surrounding technologies applicable to dried blood spot bioanalysis and commentary by internationally recognized experts.

FOREWORD
- Neil Spooner
GlaxoSmithKline

COMMENTARY
- Pharmacokinetic considerations as to when to use dried blood spot sampling
Gary Emmons, Sanofi-Aventis & Malcom Rowland, University of Manchester

CONFERENCE REPORT
- EBF Workshop on Connecting Strategies on Dried Blood Spots-conference report
Philip Timmerman, Johnson and Johnson

EDITORIALS
- Increasing Efficiency for Dried Blood Spot Analysis: Prospects for Automation and Simplified Sample Analysis
Roger Pham, Amgen

- The application of Dried Blood Sampling in global clinical trials
Peter van Amsterdam, Abbott

REVIEW
- Dried blood spots in HIV monitoring: applications in resource-limited settings
Asgeir Johannessen, Oslo University Hospital, Ulleval

SPECIAL REPORT
- A powerful couple in the future of clinical biochemistry: the in situ analysis of Dried Blood Spot by Ambient Mass Spectrometry
Gaetano Corso, Medical Faculty of University of Foggia

RESEARCH ARTICLES
- Effect of Storage Conditions on the Weight and Appearance of Dried Blood Spot Samples on Various Cellulose Based Substrates
Phil Deniff
GlaxoSmithKline

- High sensitivity assay for the determination of zatebradine in dried spot of human blood at pg/mL level using HILIC chromatography tandem mass spectrometry
Marco Michi
GlaxoSmithKline

- Sensitive determination of a drug candidate in dried blood spots using a TLC-MS interface integrated into a column-switching LC-MS/MS system
Katja Heinig, Thomas Wirz & Almudena Gajate-Perez
Roche

- Development and Validation of an HPLC/MS/MS Method for the Analysis of Dexamethasone from Pig Synovial Fluid Using Dried Blood Spotting
Chad Christianson
Alturas Analytical

- Utility of Dried Blood Spot Sampling and Storage for Increased Stability of Photo-Sensitive Compounds
Chester L. Bowen, Matthew D. Hemberger, Jonathan R. Kehler, and Christopher A. Evans
GlaxoSmithKline

- Assay for screening 6 antimalarial drugs and one metabolite using dried blood spot sampling, sequential extraction and Ion trap detection
Niklas Lindegårdh and Daniel Blessborn
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

- Validation of Individual Quantitative Methods for the Determination of the Cytochrome P450 Probe Substrates Caffeine, Flurbiprofen, Midazolam, Omeprazole and Rosiglitazone in Dried Spots of Human Blood with HPLC-MS/MS Detection
Rakesh Lad
GlaxoSmithKline

Customers who bought this item also bought

• Dried Blood Spots Part 1
• Green Bioanalysis
• Discovery Bioanalysis
• Incurred Sample Reanalysis
• Reid Bioanalytical Forum
• The Blood Group Antigen FactsBook. Edition No. 3. Factsbook
• Technical Manual, 17th edition
• Molecular Diagnostics - Technologies, Markets and Companies
• Human Blood Groups. 3rd Edition
• Biomarkers - Technologies, Markets and Companies